Aquation of the ruthenium-based anticancer drug NAMI-A: A density functional study

Journal of Physical Chemistry B

Volumn 112, Issue 13, 2008, Pages 3871-3875

  Bešker, Neva ^a   Coletti, Cecilia ^a   Marrone, Alessandro ^a   Re, Nazzareno ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL REACTIONS; CHEMOTHERAPY; DENSITY FUNCTIONAL THEORY; DRUG DELIVERY; DRUG DOSAGE; POLYPEPTIDES; REACTION KINETICS; RUTHENIUM; SUBSTITUTION REACTIONS;

ANTI CANCER DRUGS; AQUATION; DENSITY FUNCTIONAL THEORY (DFT) CALCULATIONS; DENSITY-FUNCTIONAL STUDIES; EXPLICIT WATER; INTERCHANGE MECHANISM; OCTAHEDRAL COMPLEXES; RU(0001); SOLVATION ENERGIES;

PROBABILITY DENSITY FUNCTION;

ANTINEOPLASTIC AGENT; CHLORIDE; DIMETHYL SULFOXIDE; DRUG DERIVATIVE; IMIDAZOLIUM BIS(IMIDAZOLE)DIMETHYLSULFOXIDEIMIDAZOTETRACHLORORUTHENATE(III); IMIDAZOLIUM-BIS(IMIDAZOLE)DIMETHYLSULFOXIDEIMIDAZOTETRACHLORORUTHENATE(III); ORGANOMETALLIC COMPOUND; RUTHENIUM;

ARTICLE; CHEMICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; KINETICS; QUANTUM THEORY; THERMODYNAMICS;

ANTINEOPLASTIC AGENTS; CHLORIDES; COMPUTER SIMULATION; DIMETHYL SULFOXIDE; KINETICS; MODELS, CHEMICAL; ORGANOMETALLIC COMPOUNDS; QUANTUM THEORY; RUTHENIUM; THERMODYNAMICS;

EID: 45849126175     PISSN: 15206106     EISSN: None     Source Type: Journal    
DOI: 10.1021/jp800411g     Document Type: Article

References (39)

1. (a) Keppler, B. K. In Progress in Clinical Biochemistry and Medicine; Springer: Berlin, 1989; Vol. 10, p 41.
2. (b) Clarke, M. J. In Metal Complexes in Cancer Chemotherapy; Keppler, B. K., Ed.; VCH: Weinheim, 1993; p 129.
3. (c) Keppler, B. K., Lipponer, K. G., Stenzel, B.; Kratz, F. In Metal Complexes in Cancer Chemotherapy; Keppler, B. K., Ed.; VCH: Weinheim, 1993; pp 187-220.
4. (d) Clarke, M. J.; Zu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511-2533.
5. (e) Clarke, M. 3. Coordination Chem. Rev. 2002, 232, 69-93.
6. (a) Ang, W. H.; Dyson, P. J. Eur. J. Inorg. Chem. 2006, 4003-4018.
7. (b) Brabec, V.; Novakova, O. Drug Resist. Update 2006, 9, 111 -122.
8. (a) Reedijk, J. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 3611.
9. (b) Allardyce, C. S.; Dyson, P. J.; Platinum Met. Rev. 2001, 45, 62-69.
10. Frasca, D.; Ciampa, J.; Emerson, J.; Umans, R. S.; Clarke, M. J. Met.-Based Drugs 1996, 3, 197-209.
11. Galanski, M.; Arion, V. B.; Jakupec, M. A.; Keppler, B. K. Curr. Pharm. Des. 2003, 9, 2078-2089.
12. (a) Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. J. Inorg. Biochem. 2006, 100, 891-904.
13. (b) Jakupec, M. A.; Arion, V. B.; Kapitza, S.; Reisner, V; Eichinger, A.; Pongratz, M.; Marian, B.; Graf, N.; Keyserlingk, V.; Keppler, B. K. Int. J. Clin. Pharmacol. Ther. 2005, 43, 595-596.
14. Kapitza, S.; Pongratz, M.; Jacupec, M. A.; Heffeter, P.; Berger, W.; Lackinger, L.; Keppler, B. K.; Marian, B. J. Cancer Res. Clin. Oncol. 2005, 131, 101-110.
15. Sava, G.; Pacor, S.; Mestroni, G.; Alessio, E. Anti-Cancer Drugs 1992, 3, 25-31.
16. (a) Sava, G.; Gagliardi, R.; Bergamo, A.; Alessio, E.; Mestroni, G. Anticancer Res. 1999, 19, 969-972.
17. (b) Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Curr. Top. Med. Chem. 2004, 4, 1525-1535.
18. (c) Rademaker-Lakhai, J. M.; Van Den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. Clin. Cancer Res. 2004, 10, 3717-3727.
19. (a) Bouma, M.; Nuijen, B.; Jansen, M. T.; Sava, G.; Flaibani, A.; Bult, A.; Beijnen, J. H. Int. J. Pharm. 2002, 248, 239-246.
20. (b) Bouma, M.; Nuijen, B.; Jansen, M. T.; Sava, G.; Flaibani, A.; Bult, A.; Beijnen, J. H. J. Pharm. Biomed. Anal. 2002, 30, 1287-1296.
21. Mestroni, G.; Alessio, E.; Sava, G.; Pacor, S.; Coluccia, M.; Bocarelli, A. Met.-Based Drugs 1994, 1, 41-63.
22. Sava, G.; Bergamo, A.; Zorzet, S.; Gava, B.; Casarsa, C.; Cocchietto, M.; Furlani, A.; Scarcia, V.; Serli, B.; Iengo, E.; Alessio, E.; Mestroni, G. Eur. J. Cancer 2002, 38, 427-435.
23. (a) Chen, J. C.; Li, J.; Qian, L.; Zheng, K. C. J. Mol. Struct. (THEOCHEM) 2005, 728, 93-101.
24. (b) Scolaro, C.; Geldbach, T. J.; Rochat, S.; Dorcier, A.; Gossens, C.; Bergamo, A.; Cocchietto, M.; Tavernelli, I.; Sava, G.; Rothlisberger, U.; Dyson, P. J. Organometallics 2006, 25, 756-765.
25. Chen, J.; Chen, L.; Liao, S.; Zheng, K.; Ji, L. J. Phys. Chem B 2007, 111, 7862-7869.
26. Jaguar 6.0; Schrodinger, LLC: New York, 2005.
27. (a) Becke, A. D. J. Chem. Phys. 1993, 98, 5648-5652.
28. (b) Becke, A. D. Phys. Rev. A 1988, 38, 3098-3100.
29. (a) Niu, S.; Hall, B. M. Chem. Rev. 2000, 100, 353.
30. (b) Nielsen, R. J.; Keith, J. M.; Stoltz, B. M.; Goddard, W. A., III J. Am. Chem. Soc. 2004, 126, 7967-7974.
31. Hay, P. J.; Wadt, W. R. J. Chem. Phys. 1985, 82, 299-310.
32. Hariharan, P. C.; Pople, J. A. Chem. Phys. Lett. 1972, 16, 217-219.
33. Tannor, D. J.; Marten, B.; Murphy, R.; Friesner, R. A.; Sitkoff, D.; Nicholls, A.; Ringnalda, M.; Goddard, W. A., III; Honig, B. J. Am. Chem. Soc. 1994, 116, 11875-11882.
34. McLean, A. D.; Chandler, G. S. J. Chem. Phys. 1980, 72, 5639-5648.
35. Alessio, E.; Balducci, G.; Lutman, A.; Mestroni, G.; Calligaris, M.; Attia, W. M. Inorg. Chim. Acta. 1993, 205, 205-217.
36. (a) Rotzinger, F. P. Chem. Rev. 2005, 105, 2003-2037 and references therein.
37. (b) Rotzinger, F. P. J. Phys. Chem B 2005, 109, 1510-7869.
38. (c) Aebischer, N.; Sidorenkova, E.; Ravera, M.; Laurenczy, G.; Osella, D.; Weber, J.; Merbach, A. E. Inorg. Chem. 1997, 36, 6009-6020.
39. B is the Boltzmann constant, T is the absolute temperature, h is the Planck constant, and ΔG is the activation free energy.